Our data demonstrated that the injection of non-diabetic plasma could be a promising therapeutic strategy to reverse diabetes-induced systemic inflammation and insulin resistance through inhibiting inflammatory cytokines. The gene discussed is INS; the disease is diabetes mellitus.